Taconic Biosciences Expands Immuno-oncology Animal Model Portfolio
Critical Jh Syngeneic Tumor Model Host Now Available on a B6 Background
RENSSELAER, N.Y., Jan. 18, 2021 (GLOBE NEWSWIRE) Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio.
Immuno-oncology is a leading research priority because it uses the body s own immune system to effectively treat some types of cancer. Syngeneic tumor animal models play a critical role because they use standard inbred mice that have a competent immune system, which is required to evaluate immune-modulating therapies. These models are engrafted with mouse tumors derived from the same strain background; this genetic similarity between tumor and host prevents the host from rejecting the tumor.